November 28, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing...
November 08, 2018Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m., ET
Q3 2018 and Recent Corporate Highlights: Completed $63.9 million upsized initial public offering Announced co-development agreement with Amgen and in-licensing of PRV-015 (Amgen's AMG-714), a...
November 05, 2018Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
THOUSAND OAKS, Calif. and OLDWICK, N.J. – (Nov. 5, 2018) – Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated...
November 01, 2018Provention Bio to Report Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 8, 2018
Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and...
October 23, 2018Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis- Top-line data from the "PULSE" clinical trial expected in the second quarter of 2019
Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated diseases, announced today that it has completed enrollment in the Phase 1b clinical trial...